Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Corestem Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is distributed across 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution focus at this stage. The presence of 1 distinct art unit suggests that the portfolio's current active matters are confined to a specific technical niche within the broader biotechnology sector.
The busiest examiner for this portfolio is NOBLE, MARCIA STEPHENS, who is responsible for 1 pending. Because this examiner handles the entirety of the company's pending workload, the progression of the portfolio is currently dependent on the specific examination pace and tendencies of this individual. Practitioners should monitor the historical allowance rates of this examiner to anticipate potential hurdles in the Biotechnology & Pharmaceuticals space.
The concentration of the workload in 1 distinct art unit simplifies the administrative tracking for this portfolio. The reliance on 1 distinct examiner means that any delays or specific requirements from NOBLE, MARCIA STEPHENS will directly impact the total pending volume. This focused activity reflects a direct engagement with the patent office that requires careful management of the relationship with the identified examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786483 | METHOD OF MICROGLIA DIFFERENTIATION CAPABLE OF SECURING LARGE QUANTITY OF MICROGLIA BY USING 3D ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | NOBLE, MARCIA STEPHENS | 28d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786483 | METHOD OF MICROGLIA DIFFERENTIATION CAPABLE OF SECURING LARGE QUANTITY OF MICROGLIA BY USING 3D ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | NOBLE, MARCIA STEPHENS | 28d |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17786483 | METHOD OF MICROGLIA DIFFERENTIATION CAPABLE OF SECURING LARGE QUANTITY OF MICROGLIA BY USING 3D ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | NOBLE, MARCIA STEPHENS | 1632 | §102§103§112 | Non-Final OA | 28d | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial